- Home
- CBRE vs BDX Comparison
CBRE vs BDX Comparison
Compare CBRE & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | BDX |
|---|---|---|
| Founded | 1906 | 1897 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5B | 43.0B |
| IPO Year | 2001 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CBRE | BDX |
|---|---|---|
| Price | $149.01 | $189.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $177.86 | ★ $186.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ 22.61 | N/A |
| EPS | ★ 1.77 | 1.59 |
| Revenue | ★ $40,550,000,000.00 | $21,840,000,000.00 |
| Revenue This Year | $14.31 | N/A |
| Revenue Next Year | $9.06 | $3.02 |
| P/E Ratio | ★ $84.95 | $119.63 |
| Revenue Growth | ★ 13.37 | 8.24 |
| 52 Week Low | $121.69 | $140.11 |
| 52 Week High | $174.27 | $213.08 |
Technical Indicators
Market Signals| Indicator | CBRE | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 69.72 |
| Support Level | $148.76 | $188.28 |
| Resistance Level | $155.74 | $196.36 |
| Average True Range (ATR) | 3.81 | 3.91 |
| MACD | -0.30 | -0.01 |
| Stochastic Oscillator | 56.43 | 75.86 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm managed over $155 billion (at year-end 2025) for clients across diverse public and private real estate strategies.
About BDX Becton Dickinson and Company
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.